Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
McKinsey
Moodys
Baxter
AstraZeneca
Harvard Business School

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for NBI-98854

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for NBI-98854?

NBI-98854 is an investigational drug.

There have been 36 clinical trials for NBI-98854. The most recent clinical trial was a Phase 3 trial, which was initiated on September 14th 2018.

The most common disease conditions in clinical trials are Dyskinesias, Tourette Syndrome, and Syndrome. The leading clinical trial sponsors are Neurocrine Biosciences, AbbVie (prior sponsor, Abbott), and Chinese PLA General Hospital.

There are seven US patents protecting this investigational drug and twenty-six international patents.

Recent Clinical Trials for NBI-98854
TitleSponsorPhase
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's DiseaseHuntington Study GroupPhase 3
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington's DiseaseNeurocrine BiosciencesPhase 3
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Pediatric Subjects With Congenital Adrenal HyperplasiaNeurocrine BiosciencesPhase 2

See all NBI-98854 clinical trials

Clinical Trial Summary for NBI-98854

Top disease conditions for NBI-98854
Top clinical trial sponsors for NBI-98854

See all NBI-98854 clinical trials

US Patents for NBI-98854

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
NBI-98854   Start Trial Pharmaceutical formulations Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
NBI-98854   Start Trial Pharmaceutical compounds Biovail Laboratories International (Barbados) S.R.L. (Christ Church, BB)   Start Trial
NBI-98854   Start Trial Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
NBI-98854   Start Trial Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
NBI-98854   Start Trial Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (La Jolla, CA)   Start Trial
NBI-98854   Start Trial Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 Auspex Pharmaceuticals, Inc. (LaJolla, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for NBI-98854

Drugname Country Document Number Estimated Expiration Related US Patent
NBI-98854 Canada 2938244 2034-02-07   Start Trial
NBI-98854 Eurasian Patent Organization 201691582 2034-02-07   Start Trial
NBI-98854 European Patent Office 3102190 2034-02-07   Start Trial
NBI-98854 Israel 246978 2034-02-07   Start Trial
NBI-98854 South Korea 20160117596 2034-02-07   Start Trial
NBI-98854 Mexico 2016010213 2034-02-07   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Medtronic
Merck
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.